Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Xlife Sciences AG's Days Sales Outstanding or its related term are showing as below:
XSWX:XLS'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 176.84 Med: 1259.57 Max: 7952.13
Current: 7952.13
During the past 8 years, Xlife Sciences AG's highest Days Sales Outstanding was 7952.13. The lowest was 176.84. And the median was 1259.57.
XSWX:XLS's Days Sales Outstanding is ranked worse than 98.8% of 835
companies
in the Biotechnology industry
Industry Median: 68.83
vs XSWX:XLS: 7952.13
Xlife Sciences AG's Days Sales Outstanding
declined
from Dec. 2024 (3,303.25) to Dec. 2025 (0.00).
Warning Sign:
If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.
Xlife Sciences AG (XSWX:XLS) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Xlife Sciences AG Days Sales Outstanding Related Terms
Xlife Sciences AG Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Xlife Sciences AG's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:XLS vs VRTX, REGN, RVMD: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Xlife Sciences AG's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xlife Sciences AG Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Xlife Sciences AG's Days Sales Outstanding falls into.
Xlife Sciences AG Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xlife Sciences AG (XSWX:XLS) has a Days Sales Outstanding of 0.00 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Xlife Sciences AG and its competitors. Over the past decade, Xlife Sciences AG's Days Sales Outstanding has ranged from 176.84 to 7,952.13. According to the industry distribution chart, Xlife Sciences AG ranks #825 out of 835 companies in the Biotechnology industry, placing it in the top 98.8%.
Is Xlife Sciences AG's Days Sales Outstanding too high?
Xlife Sciences AG's current Days Sales Outstanding is 0.00. Over the past 10 years, this metric has ranged from a low of 176.84 to a high of 7,952.13. Based on the distribution chart, Xlife Sciences AG ranks #825 out of 835 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Xlife Sciences AG has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xlife Sciences AG ranks #825 out of 835 companies for Days Sales Outstanding. This places Xlife Sciences AG in the lower half of its industry. The industry median Days Sales Outstanding is 68.83. Historically, Xlife Sciences AG's own Days Sales Outstanding has ranged from 176.84 to 7,952.13 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.83, based on 835 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Xlife Sciences AG and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xlife Sciences AG's current Days Sales Outstanding is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.16, compared to a current price of CHF16.50 — trading 130.4% above its estimated fair value. The current Days Sales Outstanding is 0.00. Xlife Sciences AG's overall GF Score™ is 52/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current Days Sales Outstanding is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?
Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued.
The current stock price of CHF16.50 is trading 130.4% above its estimated GF Value™ of CHF7.16.
GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.
Key valuation signals for XSWX:XLS:
Days Sales Outstanding: 0.00
GF Value™: CHF7.16 vs. price of CHF16.50 (130.4% above fair value)
No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
52GF Score
Get the complete analysis for XSWX:XLS
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:XLS has been successfully added to your 
